All articles by Phillip Broadwith
-
OpinionDeadly reminders of the importance of risk assessment
Serious incidents in two university labs highlight the importance of knowing what to do when things go wrong
-
BusinessInvestigation flags chemical incompatibility in deadly US incident
Mixing nitric acid with sodium trithiocarbonate at Catalyst Refiners formed hydrogen sulfide
-
OpinionArtificial intelligence or clever artifice?
It’s important to be realistic about what AI can, and can’t, achieve, across the chemistry enterprise
-
OpinionMessy megamergers
Rumoured merger between AstraZeneca and Bristol Myers Squibb has collapsed, and that’s probably a good thing
-
PodcastThermo Fisher data manipulation & the shrinking chemical recycling industry
We discuss fabricated images in Thermo Fisher’s online catalogue. And, what barriers are preventing chemical plastic recycling from taking off?
-
OpinionTrump threatens generic drug tariffs
Plan aims to encourage domestic US supplies, but will it work?
-
OpinionWhere does chemical recycling of plastics go from here?
US and EU plant closures highlight economic difficulties of scaling technology alongside associated policy and infrastructure
-
OpinionTrust is easily broken and hard to rebuild
Thermo Fisher needs to be open and honest about data manipulation to reassure researchers
-
OpinionIs industry getting more or less safe?
US figures suggest an increase in incidents involving serious injuries and fatalities in recent years
-
PodcastAn update on the Strait of Hormuz & potential explosives at an Antarctic base
Will temporarily reopening the Strait of Hormuz ease rising costs of resources? Plus, why are (possibly) explosive chemicals suspected to be present at a historical Antarctic base?
-
OpinionShould the EU stop exports of pesticides it has banned?
Agrochemicals including paraquat remain legal elsewhere, prompting questions over regulatory responsibility
-
BusinessEvonik to cut a further 3200 jobs by 2029
Most cuts will be in Germany, adding to the firm’s 2800 jobs shed between 2023 and 2026
-
OpinionGSK agrees $10 billion deal for Nuvalent cancer drugs
Deal includes two late-stage molecules to augment GSK’s renewed cancer therapy pipeline
-
OpinionHow far will EU push for fairer trade with China?
Strengthening rules on pharmaceutical and chemical trade could protect critical industries
-
BusinessAkzoNobel rejected attempts to cut in on Axalta merger
€13 billion counter-offer by Nippon Paints and Sherwin-Williams ‘undervalues’ the company
-
OpinionBritish Steel’s nationalisation plan contrasts against chemical industry decline
UK steel production has been declining for decades thanks to high costs and cheap imports
-
OpinionIran war’s global impact keeps growing
Shortages of bitumen, cooking gas and jet fuel are pushing up prices and disrupting construction
-
Business26 killed in fireworks factory explosion in China
Incident on 4 May injured over 60 others, with rescue work hampered by further fires and explosions
-
OpinionPurdue Pharma’s opioid prosecution enables bankruptcy settlement
$5 billion criminal sentence paves the way for resolution of civil liabilities through bankruptcy court
-
OpinionMajor drug regulators advancing routes to reduce animal testing
US, UK and EU all have goals to eliminate animal testing